



Acrylamide Risk Assessment

Susan Ferenc, D.V.M., Ph.D.
Meeting of the CIC, October 17, 2003,
Sacramento, CA

NSRL Risk Assessment Process

- Risk Characterization is the first step:
Determine Acceptable Level of Risk (ALR)
 - 1×10^{-5} or 1 in 100,000
- Dose-response assessment characterized by EPA Cancer Slope Factor (CSF)
 - 4.5
- Exposure assessment characterized by calculation of a “No Significant Risk Level” (NSRL) level of exposure on a daily basis, for life
 - $ALR/CSF \sim 0.2 \mu\text{g}/\text{day}$

Planned Risk Assessments on Acrylamide

- EPA review for IRIS database
- FDA quantitative risk assessment
- JECFA risk assessment for international standards

Dose-Response Assessment

- Uncertainties and Data Gaps
- Critical Research

Exposure Assessment

- Uncertainties and Data Gaps
- Critical Research

Risk Characterization

- Consensus the world-over is that there is insufficient data to conduct a comprehensive risk assessment at this time
- Results from research currently underway or soon to begin will address data gaps so full risk assessments, including risk characterization, can be conducted